Liver function after combined selective internal radiation therapy or sorafenib monotherapy in advanced hepatocellular carcinoma

Ricke J., Schinner R., Seidensticker M., Gasbarrini A., van Delden O. M. , Amthauer H., ...More

JOURNAL OF HEPATOLOGY, vol.75, no.6, pp.1387-1396, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 75 Issue: 6
  • Publication Date: 2021
  • Doi Number: 10.1016/j.jhep.2021.07.037
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
  • Page Numbers: pp.1387-1396
  • Keywords: ALBI score, Hepatocellular carcinoma, Radioembolization, Selective internal radiation therapy, Sorafenib, RADIOEMBOLIZATION, DISEASE, PREVENTION, Y-90
  • Hacettepe University Affiliated: Yes


Background & Aims: SORAMIC is a previously published randomised controlled trial assessing survival in patients with advanced hepatocellular carcinoma who received sorafenib with or without selective internal radiation therapy (SIRT). Based on the per-protocol (PP) population, we assessed whether the outcome of patients receiving SIRT+sorafenib vs. sorafenib alone was affected by adverse effects of SIRT on liver function.